238 related articles for article (PubMed ID: 30777099)
21. Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation.
Oh SH; Whang YM; Min HY; Han SH; Kang JH; Song KH; Glisson BS; Kim YH; Lee HY
Int J Cancer; 2012 Nov; 131(10):2253-63. PubMed ID: 22362554
[TBL] [Abstract][Full Text] [Related]
22. A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma.
Ma H; Chang H; Yang W; Lu Y; Hu J; Jin S
Mol Cancer; 2020 Jan; 19(1):4. PubMed ID: 31907020
[TBL] [Abstract][Full Text] [Related]
23. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
Erlich RB; Kherrouche Z; Rickwood D; Endo-Munoz L; Cameron S; Dahler A; Hazar-Rethinam M; de Long LM; Wooley K; Guminski A; Saunders NA
Br J Cancer; 2012 Jan; 106(1):107-15. PubMed ID: 22116303
[TBL] [Abstract][Full Text] [Related]
24. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
[TBL] [Abstract][Full Text] [Related]
25. ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer.
Bill A; Gutierrez A; Kulkarni S; Kemp C; Bonenfant D; Voshol H; Duvvuri U; Gaither LA
Oncotarget; 2015 Apr; 6(11):9173-88. PubMed ID: 25823819
[TBL] [Abstract][Full Text] [Related]
26. Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling.
Liu N; He S; Ma L; Ponnusamy M; Tang J; Tolbert E; Bayliss G; Zhao TC; Yan H; Zhuang S
PLoS One; 2013; 8(1):e54001. PubMed ID: 23342059
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.
Marshall ME; Hinz TK; Kono SA; Singleton KR; Bichon B; Ware KE; Marek L; Frederick BA; Raben D; Heasley LE
Clin Cancer Res; 2011 Aug; 17(15):5016-25. PubMed ID: 21673064
[TBL] [Abstract][Full Text] [Related]
28. Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma.
Egloff AM; Rothstein ME; Seethala R; Siegfried JM; Grandis JR; Stabile LP
Clin Cancer Res; 2009 Nov; 15(21):6529-40. PubMed ID: 19825947
[TBL] [Abstract][Full Text] [Related]
29. A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma.
De Schutter H; Kimpe M; Isebaert S; Nuyts S
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):904-12. PubMed ID: 19215824
[TBL] [Abstract][Full Text] [Related]
30. EGFR modulates complement activation in head and neck squamous cell carcinoma.
Abu-Humaidan AHA; Ekblad L; Wennerberg J; Sørensen OE
BMC Cancer; 2020 Feb; 20(1):121. PubMed ID: 32054454
[TBL] [Abstract][Full Text] [Related]
31. miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.
Zhang M; Piao L; Datta J; Lang JC; Xie X; Teknos TN; Mapp AK; Pan Q
Mol Cancer Ther; 2015 Oct; 14(10):2313-20. PubMed ID: 26227488
[TBL] [Abstract][Full Text] [Related]
32. Targeting histone deacetylases in head and neck squamous cell carcinoma: molecular mechanisms and therapeutic targets.
Xu M; Hou Y; Li N; Yu W; Chen L
J Transl Med; 2024 May; 22(1):418. PubMed ID: 38702756
[TBL] [Abstract][Full Text] [Related]
33. Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines.
Hinz TK; Kleczko EK; Singleton KR; Calhoun J; Marek LA; Kim J; Tan AC; Heasley LE
Mol Pharmacol; 2019 Dec; 96(6):862-870. PubMed ID: 31554698
[TBL] [Abstract][Full Text] [Related]
34. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
35. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes.
Chen CS; Weng SC; Tseng PH; Lin HP; Chen CS
J Biol Chem; 2005 Nov; 280(46):38879-87. PubMed ID: 16186112
[TBL] [Abstract][Full Text] [Related]
36. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
[TBL] [Abstract][Full Text] [Related]
37. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
[No Abstract] [Full Text] [Related]
38. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis.
Zhao M; Hu X; Xu Y; Wu C; Chen J; Ren Y; Kong L; Sun S; Zhang L; Jin R; Zhou X
Int J Oncol; 2019 Nov; 55(5):1165-1175. PubMed ID: 31545422
[TBL] [Abstract][Full Text] [Related]
39. Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
Baba Y; Maeda T; Suzuki A; Takada S; Fujii M; Kato Y
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134774
[TBL] [Abstract][Full Text] [Related]
40. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.
Zhang Q; Bhola NE; Lui VW; Siwak DR; Thomas SM; Gubish CT; Siegfried JM; Mills GB; Shin D; Grandis JR
Mol Cancer Ther; 2007 Apr; 6(4):1414-24. PubMed ID: 17431120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]